Abstract
Melanoma immunotherapy is an essential strategy of adjuvant treatment of melanoma and advanced metastatic melanoma. Currently, melanoma immunotherapy involves the administration of checkpoint inhibitors of anti-CTLA-4 and anti-PD-1 antibodies alone or in combination.
Despite lower therapeutic responses, immunotherapy has a longer-term therapeutic effect. At present, immunotherapy by checkpoint inhibitors is applied in the neoadjuvant treatment regimen.
This work is focused on the latest clinical studies in the adjuvant and neoadjuvant treatment of melanoma. It also discusses studies in the treatment of advanced metastatic melanoma, including the possibility of combination with targeted therapy with BRAF and MEK inhibitors.